Corrections for article DOI: 10.18632/oncotarget.2425

Alifrangis, C

Carter, P

Cereser, B

Chandrasinghe, P

Del Bel Belluz, L

Herzog, T

Krell, J

Levitan, J

Moderau, N

Schwartzberg, L

Stebbing, J

Tabassum, N

Wen, J

Oncotarget

English

We evaluated the effect of tailoring treatments based on predictions informed by tumor molecular profiles across a range of cancers, using data from Caris Life Sciences. These included breast carcinoma, colorectal adenocarcinoma, female genital tract malignancy, lung non-small cell lung cancer, neuroendocrine tumors, ovarian surface epithelial carcinomas, and urinary tract cancers.

Molecular profiles using mostly immunohistochemistry (IHC) and DNA sequencing for tumors from 841 patients had been previously used to recommend treatments; some physicians followed the suggestions completely while some did not. This information was assessed to find out if the outcome was better for the patients where their received drugs matched recommendations.

The IHC biomarker for the progesterone receptor and for the androgen receptor were found to be most prognostic for survival overall. The IHC biomarkers for P-glycoprotein (PGP), tyrosine-protein kinase Met (cMET) and the DNA excision repair protein ERCC1 were also shown to be significant predictors of outcome. Patients whose treatments matched those predicted to be of benefit survived for an average of 512 days, compared to 468 days for those that did not (P = 0.0684). In the matched treatment group, 34% of patients were deceased at the completion of monitoring, whereas this was 47% in the unmatched group (P = 0.0001)

Carter, philip

Alifrangis, CC

herzog, thomas

levitan, joel

Schwartzberg, lee

Tabassum, neha

Wen, jinrui

Spiral - Imperial College Digital Repository

Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?

Carter, Philip

Alifrangis, Costi

Cereser, Biancastella

Chandrasinghe, Pramodh

Del Bel Belluz, Lisa

Herzog, Thomas

Levitan, Joel

Moderau, Nina

Schwartzberg, Lee

Tabassum, Neha

Wen, Jinrui

Krell, Jonathan

Stebbing, Justin

Oncotarget15166www.oncotarget.comwww.oncotarget.com                                           Oncotarget, 2018, Vol. 9, (No. 19), pp: 15166-15166Correction: Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?Philip Carter1, Costi Alifrangis2, Biancastella Cereser1, Pramodh Chandrasinghe1,3, Lisa Del Bel Belluz1, Thomas Herzog4,5, Joel Levitan1, Nina Moderau1, Lee Schwartzberg6, Neha Tabassum1, Jinrui Wen1, Jonathan Krell1 and Justin Stebbing11 Department of Surgery and Cancer, Imperial College, London, UK2 Department of Oncology, University College Hospital, London, UK3 Department of Surgery, University of Kelaniya, Kelaniya, Sri Lanka4 Department of Obstetrics and Gynecology, University of Cincinnati, Cincinnati, USA5 University of Cincinnati Cancer Institute, University of Cincinnati, Cincinnati, USA6 WEST Cancer Center, The University of Tennessee, Memphis, USAPublished: March 13, 2018Copyright: Carter et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. This article has been corrected: The proper Materials and Methods and Conflicts of Interest information is as follows: MATERIALS AND METHODSThe Caris CODE database contains tumor molecular profile data for 841 patients with solid tumors (CODE version 1.0). It also includes demographic information about these patients, the drug treatments that they received before and after molecular profiling, and records of their clinical outcomes while they were still being monitored. This data was mined after web scraping the data from the Caris website, to understand if molecular characterization affected drug selection by treating physicians, and if any subtypes of molecular subsets had different outcomes across tumor types. Tables 1 and 2 describe the clinical characteristics of the patients that were profiled.The amount of time that patients were monitored varied, as shown in Figure 1. On average patients’ treatment records were available for 1018 days after diagnosis (1034 days for matched treatment patients and 1001 days for unmatched patients). On average the time of monitoring after profiling was 491 days, and the longest period of monitoring after profiling was 1906 days (the patient represented on the furthest right of Figure 1); this was 1920 days after diagnosis. The longest that records were available for any patient i.e. from diagnosis up until the last day of contact, was 12,537 days.The data were analysed independently of Caris. Patients were covered under 1 of 4 different protocols or exemptions, listed as follows. (1). The Caris Registry Protocol (TCREG-001-00-V2-1209) was approved by WIRB (WIRB Tracking #20092285) and has an NCT# of NCT02678754. (2). The Caris POA Prospective Repository (COE-001-0815) was approved by WIRB (WIRB Tracking #20162864) and has an NCT# of NCT03324841. (3). The Caris POA Retrospective Repository (COE-002-0116) was approved by WIRB (WIRB Tracking #20162657) and has an NCT# of NCT 00326499. (4). ION data is covered under an IRB exemption. All data are retrospective and have been de-identified prior to Caris receiving it and authors performing independent analyses.CONFLICTS OF INTERESTAuthors received no funding or honoraria for this publication. The data were analysed independently of Caris. Thomas Herzog and Lee S. Schwartzberg are on the scientific advisory board of Caris Life Sciences.Original article: Oncotarget. 2018; 9:9456-9467. https://doi.org/10.18632/oncotarget.24258 Correction

Correction: Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?

Philip Carter

Costi Alifrangis

Biancastella Cereser

Pramodh Chandrasinghe

Lisa Del Bel Belluz

Thomas Herzog

Joel Levitan

Nina Moderau

Lee Schwartzberg

Neha Tabassum

Jinrui Wen

Jonathan Krell

Justin Stebbing

Crossref

http://spiral.imperial.ac.uk/bitstream/10044/1/59666/2/Correction%3a%20Does%20molecular%20profiling%20of%20tumors%20using%20the%20Caris%20molecular%20intelligence%20platform%20improve%20outcomes%20for%20cancer%20patients%3f.pdf

Correction: Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?

Abstract

Similar works

Full text

Available Versions

Spiral - Imperial College Digital Repository

Spiral - Imperial College Digital Repository

Crossref